MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecul...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: San José-Enériz, Edurne, Román-Gómez, José, Jiménez-Velasco, Antonio, Garate, Leire, Martin, Vanesa, Cordeu, Lucia, Vilas-Zornoza, Amaia, Rodríguez-Otero, Paula, José Calasanz, María, Prósper, Felipe, Agirre, Xabier
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2009
Aiheet:
Short Communication
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2743636/
https://ncbi.nlm.nih.gov/pubmed/19723306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-8-69
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia